Company Overview and News

 
Centrex Metals signs phosphate rock deal with major Indian fertiliser manufacturer

2018-05-18 proactiveinvestors.com.au
Centrex Metals Limited (ASX:CXM) has signed a memorandum of understanding (MOU) with Gujarat State Fertilisers & Chemicals Ltd (NSE:GSFC) for the supply of product from its Ardmore Phosphate Rock Project in Queensland.

 
Centrex Metals targets 2018 feasibility study and first phosphate production in 2019

2018-01-15 proactiveinvestors.com.au
Centrex Metals Limited’s (ASX:CXM) scoping study for its Ardmore Phosphate Rock Project located in Queensland is the first major milestone in what will be a very active year.

 
Centrex Metals Ltd defines maiden resource at phosphate rock project

2017-07-06 proactiveinvestors.com.au
Centrex Metals Ltd (ASX:CXM) has defined a maiden inferred resource of 12 million tonnes at 28.7% phosphorus for its Ardmore Phosphate Rock Project in North West Queensland.

 
Former head of Chinese steel company with links to Australia jailed

2017-06-02 theage.com.au
Beijing: He was once one of China's most powerful steel executives, buying iron ore in quantities that fuelled Australia's economic boom.

 
Former head of Chinese steel company with links to Australia jailed

2017-06-02 smh.com.au
Beijing: He was once one of China's most powerful steel executives, buying iron ore in quantities that fuelled Australia's economic boom.

 
Centrex Metals to receive $2.2M from iron joint ventures

2016-10-17 proactiveinvestors.com.au
The companies have mutually agreed to wind-up the joint venture in light of current and forecast iron ore market conditions and to resolve the legal disputes between each other. Both companies have also agreed to return a large proportion of funding held by their related magnetite joint venture company Eyre Iron Pty Ltd back to shareholders. Centrex’s share of this return is $926,000. Funds are due to be transferred within 7 days.

 
Centrex Metals Ltd steps into prefeasibility study for potassium project

2016-09-05 proactiveinvestors.com.au
Centrex Metals Ltd (ASX:CXM) has appointed Canadian based potash engineering company Novopro for a prefeasibility study of its Oxley Potassium Project in the midwest of Western Australia. The work will include analysis and optimisation of a planned hydrometallurgical circuit, developed as part of a positive scoping study completed last month. The prefeasibility study will consider not only a start-up potassium nitrate (NOP) specialty fertiliser operation, but also cover second stage expansion into the bulk potassium fertiliser market.

 
New Research to Improve Molten Salt Applications for Renewables

2016-06-27 renewableenergyworld
Molten salt technology is being developed for use in mineral processing in the mining industry to reduce energy and water costs.

 
 
Appendix 3Y Mr J Hazel

2016-03-21 asx.com.au

 
Half Yearly Report and Accounts

2016-03-15 asx.com.au

 
Trading Halt

2016-03-07 asx.com.au

 
Port Spencer Update

2016-03-04 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...